

ICMJE DISCLOSURE FORM

Date: 15/03/2024
Your Name: PABLO CORRAL
Manuscript Title: Colesterol asociado a lipoproteína de baja densidad (cLDL) y enfermedad cardiovascular aterosclerótica: ¿es necesaria más evidencia para atribuir su rol causal?
Manuscript Number (if known): http://dx.doi.org/10.7775/rac.es.v92.i2.20477

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
Time frame: Since the initial planning of the work											
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="height: 20px;"></td><td style="width: 20%;"></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> <tr><td colspan="2" style="text-align: right; font-size: small;">Click the tab key to add additional rows.</td></tr> </table>								Click the tab key to add additional rows.	
Click the tab key to add additional rows.											
Time frame: past 36 months											
2	Grants or contracts from any entity (if not indicated in item #1 above).	None <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="height: 20px;">Amgen</td><td style="width: 20%;"></td></tr> <tr><td style="height: 20px;">PTC</td><td></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> </table>		Amgen		PTC					
Amgen											
PTC											
3	Royalties or licenses	☒ None <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="height: 20px;"></td><td style="width: 20%;"></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)																						
4	Consulting fees	☒ None <table border="1" data-bbox="383 266 1516 401"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>																							
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None <table border="1" data-bbox="383 506 1516 863"> <tr><td>Amgen</td><td></td></tr> <tr><td>Novartis</td><td></td></tr> <tr><td>PTC</td><td></td></tr> <tr><td>Gador</td><td></td></tr> <tr><td>Servier</td><td></td></tr> <tr><td>Pfizer</td><td></td></tr> <tr><td>Bago</td><td></td></tr> <tr><td>TEVA</td><td></td></tr> <tr><td>Baliarda</td><td></td></tr> <tr><td>Boheringer</td><td></td></tr> <tr><td>Novo Nordisk</td><td></td></tr> </table>		Amgen		Novartis		PTC		Gador		Servier		Pfizer		Bago		TEVA		Baliarda		Boheringer		Novo Nordisk	
Amgen																									
Novartis																									
PTC																									
Gador																									
Servier																									
Pfizer																									
Bago																									
TEVA																									
Baliarda																									
Boheringer																									
Novo Nordisk																									
6	Payment for expert testimony	None <table border="1" data-bbox="383 970 1516 1071"> <tr><td>Gador</td><td></td></tr> <tr><td>Novartis</td><td></td></tr> <tr><td>PTC</td><td></td></tr> </table>		Gador		Novartis		PTC																	
Gador																									
Novartis																									
PTC																									
7	Support for attending meetings and/or travel	☒ None <table border="1" data-bbox="383 1178 1516 1278"> <tr><td>Boheringer</td><td></td></tr> <tr><td>Gador</td><td></td></tr> <tr><td>Novartis</td><td></td></tr> </table>		Boheringer		Gador		Novartis																	
Boheringer																									
Gador																									
Novartis																									
8	Patents planned, issued or pending	☒ None <table border="1" data-bbox="383 1386 1516 1486"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>																							
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None <table border="1" data-bbox="383 1593 1516 1694"> <tr><td>MSD</td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		MSD																					
MSD																									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ None <table border="1" data-bbox="383 1801 1516 1902"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>																							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ None 	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None 	
13	Other financial or non-financial interests	☒ None 	
Please place an "X" next to the following statement to indicate your agreement: ☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.			



Pablo Corral

ICMJE DISCLOSURE FORM

Date: 15/03/2024
Your Name: AUGUSTO LAVALLE COBO
Manuscript Title: Colesterol asociado a lipoproteína de baja densidad (cLDL) y enfermedad cardiovascular aterosclerótica: ¿es necesaria más evidencia para atribuir su rol causal?
Manuscript Number (if known): <http://dx.doi.org/10.7775/rac.es.v92.i2.20477>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.


		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work									
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table> Click the tab key to add additional rows.							
Time frame: past 36 months									
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
3	Royalties or licenses	☒ None <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)												
4	Consulting fees	None <table border="1"> <tr><td></td></tr> <tr><td></td></tr> <tr><td></td></tr> <tr><td></td></tr> </table>													
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ None <table border="1"> <tr> <td>Gador</td> <td>NovoNordisk</td> </tr> <tr> <td>Elea</td> <td>Novartis</td> </tr> <tr> <td>Raffo</td> <td>Baliarda</td> </tr> <tr> <td>Boheringer Ingelheim</td> <td>Astra Zeneca</td> </tr> <tr> <td>PTC</td> <td>Bagó</td> </tr> <tr> <td>Servier</td> <td></td> </tr> </table>		Gador	NovoNordisk	Elea	Novartis	Raffo	Baliarda	Boheringer Ingelheim	Astra Zeneca	PTC	Bagó	Servier	
Gador	NovoNordisk														
Elea	Novartis														
Raffo	Baliarda														
Boheringer Ingelheim	Astra Zeneca														
PTC	Bagó														
Servier															
6	Payment for expert testimony	☒ None <table border="1"> <tr><td>Bayer</td><td></td></tr> <tr><td>Gador</td><td></td></tr> <tr><td>Raffo</td><td></td></tr> <tr><td>GSK</td><td></td></tr> </table>		Bayer		Gador		Raffo		GSK					
Bayer															
Gador															
Raffo															
GSK															
7	Support for attending meetings and/or travel	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>													
8	Patents planned, issued or pending	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>													
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None <table border="1"> <tr><td>Bayer</td><td></td></tr> <tr><td>NovoNordisk</td><td></td></tr> <tr><td></td><td></td></tr> </table>		Bayer		NovoNordisk									
Bayer															
NovoNordisk															
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>													

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None	
13	Other financial or non-financial interests	☒ None	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.



Augusto Lavalle Cobo